Commentary: Meta-analysis of Individual Participants' Data in Genetic Epidemiology
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Received for publication October 9, 2001; accepted for publication March 14, 2002. With more than 30,000 human genes and several genetic markers per gene, the potential for identifying genetic associations for various diseases is enormous (1–5). Genetic effects are often modest: Many subjects must be studied, and single epidemiologic studies are unlikely to be definitive. Meta-analysis may help meet the challenge of synthesizing data from studies of genetic epidemiology (6). Several meta-analyses of published literature (MPL) have already appeared in the field (7). Meta-analysis of epidemiologic studies (8) is controversial. Critics have focused on variability in study designs, poor data quality, insufficient confounder adjustment, publication bias, and spuriously narrow confidence intervals (9–12). Use of the raw information from individual subjects instead of published data avoids some of these problems. Meta-analysis of individual patient data has been applied successfully in randomized trials (13, 14). The equivalent design in observational epidemiology (15) may be called meta-analysis of individual participants’ data (MIPD), since observational studies may also include healthy subjects. In 1997, we conducted an MPL of host genetic effects in human immunodeficiency virus type 1 (HIV-1) disease progression. This topic was becoming prominent in the biomedical literature (16–18), and varying conclusions of investigators generated extensive controversy (19–22). Considerable bench research was being conducted to evaluate these epidemiologic associations (23, 24). We followed the MPL with an MIPD on the same topic. This project became one of the first applications of MIPD in human genetics (25) and, to our knowledge, the first involving time-to-event data. Our work provides an opportunity to evaluate the potential advantages and difficulties of conducting a large-scale MIPD in genetic epidemiology. Here we present some insights gained in the process. The MPL examined the effect of a 32-base pair deletion (Δ32) in the C-C chemokine receptor 5 gene (CCR5) and the 64I allele in the C-C chemokine receptor 2b gene (CCR2 641), on the progression of HIV-1-infected persons to acquired immune deficiency syndrome (AIDS). These chemokine receptors are coreceptors for HIV-1 cell entry. We used published data from 10 cohorts that included 3,034 subjects with known CCR5 genotype and 2,383 subjects with known CCR2 genotype. Published data were identified from MEDLINE, AIDSLINE, and abstracts from major meetings. The MPL was reported in Nature Medicine in May 1998 (26). For the MIPD, we contacted all of the primary investigators who had published or presented data (as per the MPL search) and asked them to participate and to refer other groups who might be working in this field. An open invitation for the MIPD was also included in the MPL publication (26). A provisional protocol was distributed, commented upon, and finalized with suggestions received from coinvestigators. Data cleaning, standardization of databases, and clarification of data queries proceeded in parallel with data collection. Statistical programming was developed and refined to allow automated performance of calculations and graphic display of results. While the analyses of the CCR5 and CCR2 alleles were being completed, we decided to extend the meta-analysis to include the stromal cell-derived factor 1 (SDF-1) 3′A allele for which inconsistent published data had accrued in the interim. SDF-1 is the natural ligand for CXCR4, a major HIV-1 coreceptor. The extension of the meta-analysis to include SDF-1 3′A was justified, since this allele was debated as being potentially even more important for HIV disease progression than either CCR5 Δ32 or CCR2 64I. Interim analyses and manuscript drafts were shared with coinvestigators for comments and revisions. Some investigators may publish limited data, may take a long time to publish, or may not publish at all. Selective publication of “positive” studies causes publication bias (27, 28). An advantage of MIPD is that extended databases from published studies (e.g., genotype data for additional alleles or subjects) and data from unpublished studies can be included. Our MIPD included additional data from two cohorts that had originally published information on a limited number of patients and unpublished data from three cohorts. In the MIPD, we were able to use standardized data with a priori definitions applied consistently across participating studies, whereas the MPL was limited by inconsistent treatment of key variables across the original publications. Standardization is important for categorizing participants and for defining outcomes and the eligible follow-up period. The MIPD used consistent definitions to categorize eligible participants as seroconverters or seroprevalent subjects. Seroconverters enter a study before HIV-1 infection, while seroprevalent subjects are already infected with HIV-1 at entry into the s
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109 · cited 1×
“Selective publication of “positive” studies causes publication bias (27, 28).”
The New Genomics: Global Views of Biology
Lander, E. S. (1996) · Science · doi:10.1126/science.274.5287.536 · Cited by 1,174
Cumulative Meta-Analysis of Therapeutic Trials for Myocardial Infarction
Lau, J., Antman, E. M., Jimenez-Silva, J., Kupelnick, B., Mosteller, F., & Chalmers, T. C. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207233270406 · Cited by 1,140 · cited 1×
“If updated on a regular basis as new data appear (a cumulative meta-analysis approach (47, 48)), an MIPD may determine when there is enough evidence on the effect or lack thereof of a specific allele to establish consensus.”
Ioannidis, J. P. A. (1998) · JAMA · doi:10.1001/jama.279.4.281 · Cited by 632 · cited 1×
“Selective publication of “positive” studies causes publication bias (27, 28).”
Self-citation
Cited by
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Self-citationLiberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Self-citationLiberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Self-citationLiberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Self-citationNaj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
“and has a more direct correction for confounding sampling bia”
Metadata
- Authors
- Ioannidis, J. P. A.
- Venue
- American Journal of Epidemiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-08-01
- Volume
- 156
- Issue
- 3
- Pages
- 204-210
- ISSN
- 0002-9262 (ISSN-L)
- OpenAlex
- W1979804577
- Cited by
- 118
- References
- 4
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Commentary: Meta-analysis of Individual Participants' Data in Genetic Epidemiology. https://app.cochat.ai/papers/10.1093/aje/kwf031
- The paper
- Ioannidis, J. P. A. (2002). Commentary: Meta-analysis of Individual Participants' Data in Genetic Epidemiology. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwf031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.